Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Corporate Watchdog to Fine Pharmaceutical Companies for Unfair Practices (South Korea)

This article was originally published in PharmAsia News

Executive Summary

South Korea's Fair Trade Commission (FTC) has announced it will be taking action against 10 pharmaceutical companies for allegedly offering financial incentives to hospitals and doctors to give priority to their products. Alleged incentives included cash, rebates, dinners, and covering travel expenses. Several companies are also accused of setting wholesaler prices to keep drug costs up. The FTC has not released the exact amount of the financial penalties it will seek. Insiders speculate the fines for some companies may go as high as $108 million. These accusations are the result of a year-long investigation by the FTC into the trading practices of 11 local companies, six foreign entities, and six wholesalers. (Click here for more
Advertisement

Related Content

South Korean Fair Trade Commission Investigates Drug Makers For Offering Unethical Financial Incentives To Hospitals
Advertisement
UsernamePublicRestriction

Register

SC065728

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel